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Abstract
Author Manuscript

Background—Despite increasing opioid overdose mortality, problems persist in the availability
and quality of treatment for opioid use disorder (OUD). Three FDA-approved medications
(methadone, buprenorphine, and naltrexone) have high quality evidence supporting their use, but
most individuals with OUD do not receive them and many experience relapse following care
episodes. Developing and organizing quality measures under a unified framework such as a
Cascade of Care could improve system level practice and treatment outcomes. In this context, a
review was performed of existing quality measures relevant to the treatment of OUD and the
literature assessing the utility of these measures in community practice.

Author Manuscript

Methods—Systematic searches of two national quality measure clearinghouses (National Quality
Forum and Agency for Healthcare Research and Quality) were performed for measures that can be
applied to the treatment of OUD. Measures were categorized as structural, process, or outcome
measures. Second stage searches were then performed within Ovid/Medline focused on published
studies investigating the feasibility, reliability, and validity of identified measures, predictors of
their satisfaction, and related clinical outcomes.

*

Corresponding author at: Division on Substance Use Disorders, Columbia University Medical Center, New York State Psychiatric
Institute, 1051 Riverside Drive Unit #66, Office 3714, NY, NY 10032, United States. aw2879@cumc.columbia.edu (A.R. Williams).
Conflicts of interest
Dr. Nunes received medication or software for research studies from Alkermes and Reckitt-Benckiser. Dr. Bisaga received medication,
extended-release naltrexone, for NIH funded research studies from Alkermes. Dr. Friedmann reports having received study medication
in-kind from Alkermes and served on their Scientific Advisory Board. He also received support for training and travel from Braeburn,
and served as an expert consultant in legal proceedings for Endo Pharmaceuticals. All remaining authors report no financial
relationships with commercial interests.

Williams et al.

Page 2

Author Manuscript

Results—Seven quality measures were identified that are applicable to the treatment of OUD.
All seven were process measures that assess patterns of service delivery. One recently approved
measure addresses retention in medication-assisted treatment for patients with OUD. Twenty-nine
published studies were identified that evaluate the quality measures, primarily focused on
initiation and engagement in care for addiction treatment generally. Most measures and related
studies do not specifically incorporate the evidence base for the treatment of OUD or assess
patient level outcomes such as overdose.
Conclusion—Despite considerable progress, gaps exist in quality measures for OUD treatment.
Development of a unified quality measurement framework such as an OUD Treatment Cascade
will require further elaboration and refinement of existing measures across populations and
settings. Such a framework could form the basis for applying strategies at clinical, organizational,
and policy levels to expand access to quality care and reduce opioid-related mortality.

Author Manuscript

1. Introduction

Author Manuscript

In 2016, unintentional overdose fatalities exceeded 63,000 deaths, the great majority
involving opioids (CDC, 2017). Overdoses frequently occur among persons who were
recently discharged from detoxification programs, treatment, or criminal justice settings
(Binswanger et al., 2007; Cousins, Boland, Courtney, et al., 2015; Ravndal & Amundsen,
2010; Sordo, Barrio, Bravo, et al., 2017; Strang, Mccambridge, Best, et al., 2003).
Unintentional overdose death is often a consequence of untreated or improperly treated
opioid use disorder (OUD), reflecting a long-standing addiction treatment gap in the United
States and the difficulties patients face in accessing evidence-based care (Ghitza & Tai,
2014; Volkow, Friedan, Hyde, & Cha, 2014). Despite FDA approval of three effective
medications (methadone, buprenorphine, and XR-naltrexone) shown to reduce overdose
among patients with OUD (Degenhardt, Bucello, Mathers, et al., 2010; Lee, Friedmann,
Kinlock, et al., 2016; Lee, Nunes, Novo, et al., 2018), there remain low rates of initiation
and retention on these medications (Aletraris, Bond, & Roman, 2015; Timko, Schultz,
Cucciare, Vittorio, & Garrison-Diehn, 2016; Turner, Kruszewski, & Alexander, 2015). An
alarmingly low percentage - barely a fifth - of the 2.4 million individuals estimated to have
OUD (SAMHSA, 2017) receive any specialty care in a given year (Saloner, 2015; Wu, Zhu,
& Swartz, 2016). With only a third of those in specialty care estimated to receive one of the
three FDA-approved MAT medications during a care episode, and a 6-month retention rate
under 30–50% in most settings (Morgan, Shackman, Leff, Linas, & Walley, 2018; Timko,
Schultz, Cucciare, Vittorio, & Garrison-Diehn, 2016; Tkacz, Severt, Cacciola, & Ruetsch,
2011), only a fraction of individuals with OUD achieve long-term remission in the US
(Williams, Nunes, & Olfson, 2017).

Author Manuscript

Coincident with the intensifying opioid epidemic, there have been increasing calls for
development and use of quality measures to track and improve the quality of care for
behavioral health and implement policy strategies to identify and incentivize use of best
practices (Pincus, Scholle, Spaeth-Rublee, Hepner, & Brown, 2016). Given the proliferation
and adoption of quality measures over the past twenty years in other areas of medicine, there
is much that can be learned from quality of care frameworks that have succeeded in other
fields. Developing a cascade of care model to focus and inform interventions has been
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effective in the management of chronic health conditions including HIV (Gardner, McLees,
Steiner, del Rio, & Burman, 2010), Hepatitis C (Yehia, Schranz, Umscheid, et al., 2014), and
diabetes (Ali, Bullard, Gregg, et al., 2014). A more comprehensive framework for measuring
and improving the health care system response to the challenge of OUD could be an
important tool in reducing the harms associated with the OUD epidemic. It could, for
example, guide improvement of accreditation standards for treatment programs, data
collection and reporting, treatment planning and monitoring of key targets, and
implementation strategies to improve outcomes and reduce opioid overdose mortality
(Socias, Volkow, & Wood, 2016; Williams, Nunes, & Olfson, 2017). Perhaps most
important, such a framework could quantify the current gaps in care processes for
individuals with OUD and provide tools for goal setting, accountability, measurement of
progress, identification of needed treatment resources, and increases in the use of guidelineconsistent, evidence based care processes.

Author Manuscript
Author Manuscript

For instance, the HIV Cascade of Care framework establishes key stages through which HIV
infected persons can progress (engagement in care, antiretroviral initiation, viral
suppression, retention in care) to maximize health and eliminate transmission risk to others
(Gardner, McLees, Steiner, del Rio, & Burman, 2010). Successful progression through each
stage is dependent on satisfaction of prior stages. Adapting the cascade framework to OUD
offers an informative model for organizing quality of care measurement. The model is
premised on the concept that patients who achieve long-term recovery from opioids are
likely to do so through a stepwise process with each step dependent on success with the
prior step. It posits that patients must first engage in care in order to initiate MAT. Among
those who initiate MAT successfully, efforts are then needed to retain patients in care. As an
example, Belenko, Knight, Wasserman, et al. (2017) have demonstrated the utility of
applying the cascade framework to juvenile justice populations with substance use to detect
gaps in care and opportunities for improvement.

Author Manuscript

At the population level, effective treatment of OUD presents a series of clinical challenges
that could be addressed through development of linked quality measures. Measures could
systematically target key processes and outcomes for patients diagnosed with OUD or
following overdose. This review includes a systematic search of national quality measure
clearinghouses for measures that might be applied to the treatment of OUD, emphasizing the
four stages of an OUD Treatment Cascade once patients have already been identified as
having OUD: 1). Engagement in care, 2). MAT initiation, 3). Retention, and 4). Remission.
A search was then performed of the literature investigating the use of these measures to
assess their feasibility, reliability, importance and association with clinically meaningful
outcomes. A discussion is subsequently provided on how measures could be consolidated,
operationalized, and strengthened to improve outcomes for affected individuals across
different settings under a unified OUD Treatment Cascade framework derived from
Williams, Nunes, and Olfson (2017).

2. Methods
We performed a systematic search of two national quality measure clearinghouses
containing over 3000 healthcare quality measures currently in use by healthcare
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organizations spanning all clinical fields. The Agency for Healthcare Research and Quality
(AHRQ) is a federal agency in the Department of Health and Human Services with the
mission to produce evidence to make health care safer, higher quality, more accessible,
equitable, and affordable. AHRQ maintains a National Quality Measure Clearinghouse
(NQMC). The National Quality Forum (NQF) is a not-for-profit, nonpartisan, multistakeholder membership-based organization that works “to catalyze improvements in healthcare” and endorses measures developed by other parties such as the National Council on
Quality Assurance (NCQA), The Joint Commission, professional associations and
healthcare policy institutes such as the RAND Corporation, often supported by the Centers
for Medicaid and Medicare Services (CMS). Both the AHRQ and NQF maintain
comprehensive databases cataloging quality measures and their provenance (Goldman,
Spaeth-Rublee, Nowels, Ramanuj, & Pincus, 2016).

Author Manuscript

Within the AHRQ and NQF databases, search terms included, “opioid use disorder,” “opioid
addiction,” “heroin addiction,” “substance use disorder,” OR “substance abuse.” Measures
were included in the review if they 1). Could be applied directly to the treatment of OUD,
2). Precisely defined a numerator and denominator. Measures were excluded if they 1).
Addressed prevention, screening, or identification of OUD only (for instance, measures
regarding high dose prescribing of opioids), 2). Were not specific to the direct treatment of
OUD (for instance, screening for nicotine use among patients with OUD) or 3). Related to
general quality of care for any medical condition (for instance, the percent of hospitalized
patients counseled on discharge instructions).

Author Manuscript
Author Manuscript

Measures were further categorized as structural, process, or outcome measures (Donabedian,
1988; Garnick, Horgan, & Chalk, 2006) according to “measure domain” in the
clearinghouses. Structural measures address the capacity of a clinical organization or system
to provide effective care, such as the percentage of emergency departments with a
continuously available addiction specialist or the percentage of OUD specialty treatment
programs with at least one buprenorphine waivered physician. Structural measures can be
incorporated into accreditation standards and recognition programs. They also often include
the capacity to collect and report process and outcomes measures. Process measures assess
whether effective, evidence-based care is actually being provided, such as the percent of
patients who receive a urine drug screen or the percent of patients prescribed a MAT
medication upon intake to specialty treatment. In some health care environments, process
measures can be assessed in real time as they occur through electronic health records.
Finally, outcome measures, which often require risk adjustment based on patient
characteristics for comparative purposes, typically refer to patients’ clinical outcomes, such
as the percentage of OUD patients initiating buprenorphine with subsequent opioid negative
urines or with clinically meaningful improvements in health and quality of life (Bray et al.,
2017; Jones, Vogelman, Luba, Mumtaz, & Comer, 2017).
Although the Veterans Health Administration (VHA) has promulgated many quality
measures, it was not included in the primary search given that measures are inherently
operationalized (“specified”) for VHA populations and settings. However, we included
studies investigating use of quality measures for substance use disorders from VHA settings
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in the results along with other published literature that incorporated quality measures for
SUDs.
In addition to a search among quality measure clearinghouses for existing measures
applicable to the treatment of OUD, we performed a literature search through OVID/
Medline with MeSH terms “quality indicators, healthcare,” AND “substance-related
disorders” to search for studies that directly assessed the implementation, predictors, and
outcomes of identified quality measures. Secondary searches were performed using
backward and forward citations through Web of Science based on initial results in
combination with hand search methods to identify articles pertaining to the included
measures.

3. Results
Author Manuscript

3.1. Quality measures related to OUD treatment
Across the two clearinghouses, 131 measures were initially identified (31 in the NQF and
100 in the AHRQ databases). Of these 131, 12 met study criteria as applicable to the
treatment of OUD. Most often, measures were excluded because they pertained to general
patient satisfaction, general screening (i.e. for depression, nicotine use, access to firearms),
or general improvement on rating scales (i.e. among patients with any behavioral health
diagnosis); were related to the management of chronic pain; were related specifically to the
care of patients with HIV; or could not be applied to treatment. Five of the 12 relevant
measures were duplicates, leaving 7 unique measures (see Table 1) selected for second stage
searches.

Author Manuscript

All included measures are process measures reflecting patterns of service delivery (i.e.
percentage of patients with a SUD discharged from an emergency department who receive
specialty care within 30 days). Two were specific to the treatment of OUD including a 2017
measure developed by RAND (continuity of MAT for OUD) tracking the percent of patients
who initiate MAT that are retained on medication for a minimum of 180 days (NQF 2017).
Although this measure could serve as a patient outcome, it was constructed as a process
measure that could be considered to approximate clinical improvement. A second measure
reflected the percent of patients with OUD counseled on the existence of available
treatments. It is the only included measure to have not been endorsed by the NQF.

Author Manuscript

As of 2004, the National Committee for Quality Assurance (NCQA) has adopted two of the
identified measures into the Healthcare Effectiveness Data Information Set (HEDIS). These
two HEDIS measures initially originated from efforts by the Washington Circle, first
conceived in 1998 by SAMHSA (Garnick, Horgan, & Chalk, 2006; Garnick, Lee, Chalk, et
al., 2002; Garnick, Lee, Horgan, et al., 2009; Mccorry, Garnick, Bartlett, Cotter, & Chalk,
2000). HEDIS is the most widely used set of quality measures in the managed health care
industry, used by over 90% of managed healthcare plans’ administrators to assess quality of
care delivery but are often less familiar to front line clinicians (Harris et al., 2015; HEDIS,
2013). These two measures are related to SUDs generally but not specific to OUD: 1) the
HEDIS Initiation measure assesses the percentage of patients who have a treatment intake
within 14 days of a new SUD diagnosis, and 2) the HEDIS Engagement measure assesses
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the percentage of patients initiating treatment who have at least two additional alcohol or
other drug (AOD) services within the 30 days following Initiation (NCQA 2017). These two
measures appeared in both the AHRQ NQMC and NQF Clearinghouses. Although
applicable to the treatment of OUD, these general measures do not address evaluation for or
initiation of MAT. In 2017, the NCQA expanded the Initiation and Engagement measures to
include receipt of MAT pharmacotherapy as a qualifying service as this is often additive to,
rather than duplicative of other AOD services (Mattke, Predmore, Sloss, Wilks, & Watkins,
2017).
3.2. Publications evaluating OUD quality measures

Author Manuscript

The literature search for studies pertaining to quality measures for SUD initially returned 51
articles. Among the 51, 29 were excluded as they related only to general quality
improvement in healthcare or mental health (see Appendix for detail). An additional 11 were
excluded as they pertained to the theoretical development or operationalization of quality
indicators for addiction treatment but did not directly contribute to the development or
analysis of the 7 identified quality measures in Table 1. Finally, 4 were related to involuntary
hospitalization (2), counselor qualifications (1), or HIV-related stigma (1) rather than clinical
management of OUD.

Author Manuscript

In sum, 7 articles were found in the primary search related to the development, use (i.e.
feasibility, reliability, validity), predictors, or clinical outcomes of the included quality
measures. A secondary search was performed using backward and forward search
methodology from these 7 articles’ citation lists which yielded an additional 22 articles
related to the included measures. Among all of the articles (N = 29), 4 related to the
conceptual development of the measures (Garnick, Horgan, & Chalk, 2006; Garnick, Lee,
Horgan, et al., 2009; Mccorry, Garnick, Bartlett, Cotter, & Chalk, 2000; Thomas, Garnick,
Horgan, et al., 2011), 7 primarily related to feasibility, reliability, or validity of their use or
specification (see Table 2), 7 primarily assessed predictors of measure satisfaction (see Table
3), and 11 primarily assessed outcomes among patients satisfying specific measures (see
Table 4). However, among the 7 included measures (Table 1), only the 2 HEDIS measures of
Initiation and Engagement were directly studied in the published literature. The remaining 5
measures were not assessed across any of the 29 articles, although 4 articles (Mattke,
Predmore, Sloss, Wilks, & Watkins, 2017; Thomas, Garnick, Horgan, et al., 2011; Thomas,
Garnick, Horgan, et al., 2013; Watkins, Paddock, Hudson, et al., 2017) pertained to
expanding HEDIS Initiation and Engagement measure specification to include MAT as a
qualifying treatment service or additionally investigated outcomes with continuous use of
MAT as a process measure.

Author Manuscript

Across the 29 studies, only 4 addressed OUD specifically (Mattke, Predmore, Sloss, Wilks,
& Watkins, 2017; Thomas, Garnick, Horgan, et al., 2011; Thomas, Garnick, Horgan, et al.,
2013). The other 25 studies assessed measure development or outcomes for SUDs generally.
Several articles indicated that there is a lack of reliable and valid quality measures developed
specifically for OUD and that quality measures for SUD generally have not been specifically
tested in opioid dependent populations (Garnick, Lee, Chalk, et al., 2002; Garnick, Lee,
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Horgan, et al., 2009; Harris, Humphreys, Bowe, Tiet, & Finney, 2008; Watkins, Paddock,
Hudson, et al., 2017).

Author Manuscript

For the included measures, studies demonstrated the feasibility, reliability, and importance of
the HEDIS measures (see Table 2) among managed, private, Medicaid, and Veterans Health
Administration (VHA) plans (Garnick, Lee, Chalk, et al., 2002; Garnick, Lee, Horgan, et al.,
2011; Thomas, Garnick, Horgan, et al., 2013), although reliability was generally found to be
better in specialty settings than in non-specialty settings (Harris et al., 2015; Harris, Reeder,
Ellerbe, & Bowe, 2011). However, measure specification (i.e. technical definition for
population of interest and qualifying treatment criteria) produced differing results based on
payers (Garnick, Lee, Horgan, et al., 2011; Thomas, Garnick, Horgan, et al., 2011) as there
can be great variation across settings in patient characteristics and population-based analyses
(Thomas, Garnick, Horgan, et al., 2013). Studies specific to assessing pharmacologic
measures consistently showed the feasibility of measures assessing use of MAT as a
performance measure in systems with robust electronic health record systems (Thomas,
Garnick, Horgan, et al., 2011; Thomas, Garnick, Horgan, et al., 2013; Watkins, Paddock,
Hudson, et al., 2016).

Author Manuscript

Seven studies primarily examined predictors of meeting HEDIS initiation and engagement
measure criteria (see Table 3) for general addiction care (i.e. not specific to OUD). These
studies found higher rates of initiation and engagement when patients were identified in
specialty settings or receiving care in specialty settings (Harris & Bowe, 2008; Harris, Bowe,
Finney, & Humphreys, 2009) although primary care (Kim, Saitz, Cheng, et al., 2011) and
collaborative care initiatives have also shown to be successful (Watkins, Ober, Lamp, et al.,
2017) at engaging patients. Other studies found that patients with greater criminal justice
involvement, addiction severity, and racial/ethnic minorities often had relatively lower
probabilities of treatment initiation and engagement (Acevedo, Garnick, Dunigan, et al.,
2015; Brown, Bennett, Li, & Bellack, 2011; Lee, Garnick, O’Brien, et al., 2012) but this was
not always observed (Bensley, Harris, Gupta, et al., 2017), reflecting variation in patient
populations across settings.

Author Manuscript

Among the published studies evaluating outcomes (n = 11) after meeting HEDIS Initiation
and Engagement measures (see Table 4), these two measures have been consistently linked
to clinical improvements such as reduced drug and alcohol use and risk of detoxification
readmission (Acevedo, Garnick, Ritter, Lundgren, & Horgan, 2016; Garnick, Lee, O’Brien,
et al., 2012; Harris, Humphreys, Bowe, Tiet, & Finney, 2008; Harris, Humphreys, & Finney,
2007). Similar associations have been reported with regard to improved criminal justice
outcomes (Garnick, Horgan, Acevedo, et al., 2014; Garnick, Horgan, Lee, et al., 2007),
employment outcomes (Dunigan, Acevedo, Campbell, et al., 2014), and patient perceptions
of care (Hepner, Paddock, Watkins, et al., 2017). Despite statistical significance, however,
the strength of these associations was often clinically modest. More recent studies have
further reported that the HEDIS Initiation and Engagement measures are associated with
reduced risk of mortality (Paddock, Hepner, Hudson, et al., 2017; Watkins, Paddock,
Hudson, et al., 2016). However, a study in the VHA setting found that continuous receipt of
MAT was not associated with lower mortality (Watkins, Paddock, Hudson, et al., 2017).
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4. Discussion
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Despite the recent promulgation of thousands of quality measures across the healthcare
landscape, we found only a few measures related to SUDs that can be applied to the
treatment of OUD (n = 7). Among the seven identified unique measures (Table 1), all are
process measures that reflect patterns of service delivery. Most do not specifically
incorporate the evidence-base for the treatment of OUD or assess patient level outcomes
such as overdose. A secondary literature search for articles investigating the development,
use, predictors, and outcomes of these measures produced 29 publications. Findings are
mostly limited to the evaluation of HEDIS Initiation and Engagement measures for SUDs
generally (rather than being specific to OUD) and show modest but consistent beneficial
outcomes for patients who engage in care, including reduced mortality in some studies. The
scarcity of measures specific to OUD is problematic given the large and growing impact of
OUD on health and mortality outcomes. Since performance on generic measures of care
processes for SUD is not specifically informative of system performance in addressing OUD
(i.e., it is possible to do well on these measures by providing excellent treatment for other
SUDs but poor treatment for OUD) there is a need for stewardship of OUD-specific quality
measures.

Author Manuscript

There is a critical opportunity to organize, coordinate, and expand existing quality measures
to effectively engage patients with OUD in specialty care. Mounting evidence demonstrates
OUD is a chronic disorder requiring ongoing treatment and has unique risks (i.e. sudden
death with relapse) and treatment pathways (3 pharmacological options with differing
induction strategies) distinguishing it from other SUDs (Kampman & Jarvis, 2015;
USDHHS, 2016; Strang, Mccambridge, Best, et al., 2003; Amato, Davoli, Perucci, et al.,
2005). Effective treatment of OUD presents a series of clinical challenges; development of
quality measures provides opportunities to systematically target several points of
intervention, and could be informed by goal setting and tracking of progress at each stage
with feasible, reliable, and valid measures under a unified framework. The proposed OUD
Treatment Cascade model encompassing four key stages for patients identified with OUD,
1). Treatment engagement, 2). MAT initiation, 3). Retention, and 4). Remission could build
on existing measures to enhance patient outcomes (Williams, Nunes, & Olfson, 2017).
Coordinated measure development at structural, process, and outcome levels would likely be
most impactful.

Author Manuscript

Fig. 1 depicts the currently available measures (from Table 1) mapped onto the proposed
OUD Treatment Cascade framework, illustrating gaps in measurement and opportunities for
measure development. Fig. 1 highlights how current measures mostly address early stages of
care engagement rather than progression through the full Cascade. While the existing NCQA
HEDIS Initiation and Engagement measures are used by virtually all managed care plans
(Harris et al., 2015; HEDIS, 2013) and provide a basis for comparisons across insured
populations through the analysis of claims data, they do not offer the level of detail needed
to track individual patient progress through OUD Treatment Cascade stages. Most existing
measures address whether patients receive AOD services in general, but do not track patients
with OUD as they progress through an episode of care with evidence based treatment. For
instance, unlike that for other SUDs, the gold standard treatment for OUD emphasizes use of
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MAT without a predefined length of treatment. Although some patients may receive high
quality care for other SUDs that does not involve MAT, the evidence does not currently
support this as a first line approach for OUD. Additionally, studies such as Watkins,
Paddock, Hudson, et al., 2017 have demonstrated the limitations of general SUD measure
reliability for OUD and pitfalls of their misapplication to OUD, limiting clinical validity. For
example, in many systems, the initiation of MAT may reflect underlying addiction severity
requiring risk adjustment as a confounder for outcomes such as mortality in addition to
serving as a process measure approximating quality care.

Author Manuscript

In addition to developing measures under a unified framework to assess success along an
OUD Treatment Cascade, greater specification of measures could help to define populations
that would serve as the denominator for whom quality measures are targeted. A distinction
between acute presentations (such as overdoses or emergency department visits) and the
engagement of patients with OUD identified via routine screening and clinical management
for population-based targeting is key. This distinction highlights the opportunity acute
presentations offer for engaging patients with untreated OUD in specialty care and initiating
a MAT medication (D’Onofrio et al., 2015). For instance, the current measure assessing
receipt of a follow up AOD service after an ED visit could be applied to patients who
acutely present with an overdose. The measure assessing initiation of AOD treatment within
14 days of a new OUD diagnosis or those with OUD counseled on available treatments can
be applied to patients identified with OUD in primary care settings. Currently, many
individuals with OUD who overdose or experience complications (such as Hepatitis C, HIV
infection, or abscesses) receive acute services, but are not effectively engaged in care to treat
their underlying OUD (Frazier, Cochran, et al., 2017; Larochelle, Liebschutz, Zhang, RossDengan, & Wharam, 2016).

Author Manuscript

Fig. 2 models candidate measure concepts for each of the four proposed stages of an OUD
Treatment Cascade at the structural, process, and outcome levels for populations of patients
with OUD with acute presentations to emergency rooms, such as for a medically treated
overdose. The figure is intended to illustrate the opportunity to develop interlocking
measures to monitor patient progression through an OUD Treatment Cascade and identify
key stages where patients may struggle. Given that measure development is often a lengthy
process and must be specified for each population, researchers and policymakers should
consider prioritizing measures that are likely to be the most feasible and have the greatest
impact.

Author Manuscript

Many interventions and services for responding to the epidemic (e.g. prescription drug
monitoring programs and prescriber guidelines) address prevention and risk management but
do not specifically facilitate progression into specialty AOD treatment for individuals who
have been identified as having OUD. Greater emphasis on actively reaching and evaluating
such individuals in emergency, acute, and criminal justice settings could improve rates of
MAT initiation, especially for patients otherwise ambivalent about seeking treatment. Our
hope is that this framework will motivate development of quality measures to better assess
whether specific interventions more effectively engage individuals identified with OUD into
evidence-based specialty care or, for instance, promote initiation of MAT. These are
suggestions for measure development that require refinement over time to demonstrate an
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empiric basis of feasibility, reliability, and clinical validity to be endorsed and used by the
field.

Author Manuscript

Following approval of the ASAM Standards of Care for the Addiction Specialist Physician
in 2013 (ASAM, 2014), an ASAM Performance Measures Panel operationalized the
standards into three candidate SUD performance measures. Most notably, one measure was
tested to assess the percent of patients diagnosed with OUD in a given year who receive a
prescription for MAT at least once in the same year (using administrative claims) (Harris,
Weisner, Chalk, et al., 2016). This OUD MAT measure has been evaluated in both VHA
(Harris, Weisner, Chalk, et al., 2016) and commercially insured (Thomas, Ritter, Harris, et
al., 2018) populations demonstrating feasibility. Further stewardship of this measure would
relate to the MAT initiation stage of the OUD Treatment Cascade presented in Fig. 2. As
currently specified, this measure does not reference timeliness of MAT initiation following
intake for a given care episode.

Author Manuscript

Because the drug treatment system has historically operated outside of the general
healthcare system, policymakers and administrators have faced complex administrative
challenges to integrate addiction treatment into the modern healthcare system with
integrated EHR capabilities for continuous reporting and quality improvement (Friedmann,
Saitz, & Samet, 2003). Currently, over a third of treatment programs still do not accept
insurance of any kind (Andrews, Abraham, Grogan, et al., 2015) making the use of HEDIS
measures (originally developed to be valid using claims data alone) difficult to apply to these
settings. State agencies that oversee the funding and regulation of each state’s specialty
addiction facilities have opportunities to help their state’s treatment programs qualify for
insurance reimbursement and incentivize them to adopt adequate data collection and
reporting systems to maintain licensing and accreditation (Buck, 2011).
One strategy for improving patient outcomes along the OUD Treatment Cascade may
involve substance use disorder treatment providers (SAMHSA-accredited and private
providers) reorienting systems to track all patients who enter care for OUD, especially those
who discontinue medication treatment or stop appearing for appointments and have
presumably relapsed to active use and are at greatest risk of overdose (Barrett, Li, SpaethRublee, & Pincus, 2017; Strang, Mccambridge, Best, et al., 2003; Williams, Nunes, &
Olfson, 2017). Intensive case management with patient navigators and peer counselors can
assist programs in tracking patients outside of clinical settings. Information about
individuals who “fall off” the Cascade may motivate efforts to design interventions to
improve outcomes over time (Chalk & Mark, 2017).

Author Manuscript

There are several limitations to the use of quality measures which qualify their applicability
to an OUD Treatment Cascade. Foremost, quality measures can pose risks of regulatory
overreach and potential downsides of electronic health records and data monitoring
(Schuster, Onorato, & Meltzer, 2017). Although a given measure in isolation may be
feasible, reliable, and clinically valid, in concert with the large number of other measures, it
may prove burdensome and ultimately hamper effective clinical practice. Additionally, any
well-intended measure may inadvertently incentivize counterproductive behavior by
providers such as “denominator management,” whereby rates of accurate diagnosis are
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artificially suppressed to game the system. We have attempted to address these concerns by
proposing a unified framework that conceptualizes interlocking measures to capture
synergisms and avoid redundancy. Effective implementation strategies would benefit from
monitoring for unintended applications. Additionally, many specialty addiction treatment
providers still lack data collection and reporting systems, impeding their ability to
participate in measure assessment or eligibility for insurance reimbursement. An impetus for
further measure development concerns the lack of access to evidence based treatment that
many patients continue to face across a treatment landscape notorious for practice variation
amid a persistent gap between the science and practice of addiction treatment.

5. Limitations

Author Manuscript
Author Manuscript

The current review has some limitations. First, we limited the current study to an
investigation of quality measures contained in major national clearinghouses. As a result,
measures in other healthcare systems such as the VHA, general outcome measures used in
clinical trials, or professional society practice guidelines such as those from the American
Society of Addiction Medicine (e.g. ASAM, 2014) or American Psychiatric Association
were outside of our scope. These additional levers for improving OUD management warrant
further study. Given increasing rates of mortality among individuals with OUD despite FDA
approval of three highly effective pharmacotherapies, we decided to focus on existing
measures that could be applied to the treatment of OUD rather than to prevention or
identification in earlier stages of an OUD Cascade of Care. Second, the literature review was
conducted by the lead author (ARW) and results may have differed with a group consensus
process to screen articles. Finally, despite the increasing prominence of quality measures
across the healthcare landscape, we did not limit our review of measures or published studies
to those developed specifically for OUD as so few (e.g. two measures, according to our
findings) would have been available for assessment.

6. Conclusion

Author Manuscript

Development and strategic application of coordinated performance measures at key stages
may offer opportunities to maximize the use of evidence-based treatment and assess and
improve outcomes across settings and populations. With adoption of an OUD Treatment
Cascade as an organizing conceptual framework, quality measures could be developed and
tested systematically and iteratively refined to help maximize care outcomes. An OUD
Treatment Cascade framework could improve treatment program accreditation standards,
data collection and reporting, monitoring of key targets, and enhance outcomes. Developing
quality measures to identify which patients struggle at which stages of the Cascade could
also target clinical and policy interventions to help federal and state efforts improve patient
outcomes.
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Fig. 1.

Existing SUD quality measures and applicability to an OUD treatment cascade.
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Fig. 2.

Candidate quality measure concepts for an OUD treatment cascade at structural, process,
and outcome levels for patients treated for overdose.
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NQF clearinghouse
NQF clearinghouse
AHRQ NQMC and NQF
clearinghouse

AHRQ NQMC and NQF
clearinghouse

AHRQ NQMC and NQF
clearinghouse

AHRQ NQMC and NQF
clearinghouse

AHRQ NQMC

MAT retention for 180+ days
among MAT initiators

AOD service following
substance-related ED visit

Referrals at discharge for
inpatients with SUDs

Referrals at discharge for
inpatients with SUDs

Initiation of AOD treatment
among those with a SUD
(HEDIS Initiation measure)

Engagement in treatment among
those with a SUD
(HEDIS engagement measure)

Counseling on treatment types
for those with OUD

#004208 Percent > 18 years with current opioid addiction counseled on
psychosocial and pharmacologic treatments

#009967 identical to: #010575 Percent with engagement in AOD
treatment (2+ visits) within 30 days of initiation
(Comparable to NQF #0004 initiation and engagement of AOD
treatment)

#009966 identical to: #010574 percent with initiation AOD treatment
within 14 days of new SUD diagnosis
(Comparable to NQF #0004 Initiation and Engagement of AOD
treatment)

#010149 Percent with AOD diagnosis that receives a MAT or referral
at hospital discharge
(Comparable to NQF #1664 Sub3a: AOD treatment provided/offered at
discharge from inpatient hospitalization)

#010148 Percent with AOD diagnosis that receives or refuses a MAT
or referral at hospital discharge
(Comparable to NQF #1664 Sub3: AOD treatment provided/offered at
discharge from inpatient hospitalization)

#2605 Follow up AOD service after emergency department visit for
AOD (percent within 7 days and percent within 30 days)

#3715 Continuity of pharmacy for OUD (percent with 180+ days
retained on MAT among those who initiate MAT)

Quality measure identifying detail

APA
NCQA
PCPI

NCQA

NCQA

TJC

TJC

NCQA

RAND

Developer

N/A

2009

2009

2014

2014

2015

2017

Year
endorsed by
NQF*

Process

Process

Process

Process

Process

Process

Process

Type

Yes

No

No

No

No

No

Yes

Specific to OUD?

NQF = National Quality Forum; AOD = Alcohol or Other Drug; AHRQ NQMC = Agency for Healthcare Research and Quality National Quality Measure Clearinghouse; TJC = The Joint Commission;
PCPI = Physician Consortium for Performance Improvement.
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Quality measures related to the treatment of opioid use disorder.
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HEDIS initiation
and engagement

HEDIS initiation
and engagement

HEDIS initiation
and engagement
HEDIS initiation
and engagement
HEDIS initiation
and engagement
HEDIS initiation
and engagement
HEDIS initiation
and engagement

Garnick, Lee, Chalk,
et al., 2002

Harris, Reeder,
Ellerbe, & Bowe,
2011

Garnick, Lee,
Horgan, et al., 2011

Kim, Saitz, Cheng, et
al., 2011

Thomas, Garnick,
Horgan, et al., 2013

Harris et al., 2015

Mattke, Predmore,
Sloss, Wilks, &
Watkins, 2017

Commercial health
plan claims

VHA

National data from
private health plans,
VHA, and Medicaid

RCT in primary care
settings

Case studies of five
states

VHA

Administrative data
among commercial
MCOs

Setting

Feasibility of expanded measure specifications
to include receipt of MAT as a qualifying AOD
service

Specification validity

Feasibility of expanded measure specifications
to include receipt of MAT as a qualifying
service

Feasibility of initiation and engagement criteria
under a chronic medical disorder model

Feasibility and implementation

Validity of measure to correctly identify SUD
treatment services through diagnosis and
procedure codes

Feasibility among adult enrollees

Primary outcome

Including MAT was feasible and increased initiation
rates by 2.4% (from 38.9% to 39.8%) and
engagement rates by 9.9% (from 12.9% to 14%)

High concordance for residential and outpatient AOD
programs (90% and 96%). Concordance in nonaddiction settings ranged from 59% to 93%.

MAT as a qualifying AOD service is feasible across
systems but varies widely depending on measure
specification

Feasible in primary care with initiation and
engagement rates of 45% and 23%

Measures can be satisfactorily implemented but with
mixed implications for other states. Measures reflect
necessary but insufficient steps for full recovery.

Concordance with chart review in specialty settings
was high (range 92% to 98%). Concordance with
chart review in non-specialty settings varied from
46% to 63%).

Use of measures is feasible, meaningful, and
informative. Initiation rates ranged from 26%–46%;
Engagement rates were more consistent with a range
of 14% to 29%

Results

VHA = Veterans Health Administration; MAT = Medication assisted treatment; RCT = Randomized Controlled Trial; AOD = Alcohol or other drug.

Measure

Article

Studies evaluating use (feasibility, reliability, or validity) of quality measures applicable to OUD.

Yes

No

Yes

No

No

No

No

Specific to OUD?
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HEDIS
initiation and
engagement

HEDIS
initiation and
engagement
HEDIS
initiation and
engagement
HEDIS
initiation and
engagement
HEDIS
initiation and
engagement

Brown, Bennett,
Li, & Bellack,
2011

Lee, Garnick,
O’Brien, et al.,
2012

Acevedo,
Garnick,
Dunigan, et al.,
2015

Bensley, Harris,
Gupta, et al.,
2017

Watkins, Ober,
Lamp, et al.,
2017

Collaborative Care
intervention model
in a FQHC

Patients with
alcohol use
disorder in the
VHA

Public sector AOD
treatment centers
in 4 states

Outpatient
multisite pilot
study across 12
states; adolescents

Randomized
sample of
treatment-seeking
patients with
comorbid SMI and
SUD

VHA

VHA

Setting

RCT data including
EHR and pharmacy
logs

Administrative data

Administrative linked
with criminal justice
data

Secondary data, 28
outpatient clinics

Multisite RCT data

Administrative data

Administrative data

Data source

Rates of initiation and
engagement

Rates of initiation and
engagement

Rates of initiation and
engagement among
adolescents
Rates of engagement
with emphasis on racial
disparities
Rates of initiation and
engagement

Rates of initiation and
engagement

N = 175 patients

N = 2191
patients

N = 108,654
patients

N = 90,879
patients

N = 377 patients

Rates of initiation and
engagement

N = 270,877
patients

N = 320,238
patients

Primary outcome

Sample size

Higher rates among collaborative care
participants versus TAU: Initiation 31.6%
vs 13.7% (AOR 3.54); Engagement,
15.5% vs 4.2% (AOR 5.89)

Engagement results varied with measure
specification but were more likely for
black patients (AOR 1.1) relative to white
patients

Racial minorities often had lower
initiation and engagement rates but there
was great variation and mixed findings
across the four states

76% of the sample Initiated, with 59%
Engaged. Mixed race and highly truant
adolescents had lower initiation rates.
Latino youth were less likely to engage.

Among patients with serious mental
illness, males (AOR 0.46) and those with
schizophrenia (AOR 0.44) had lower
initiation rates. Those with current (v.
recent) drug dependence (AOR 0.30) or a
recent arrest (AOR 0.37) were less likely
to engage

Patients diagnosed with SUD in specialty
settings more likely to progress to
Initiation and Engagement but a
significant amount of AOD care occurs
outside of specialty settings in a given
system, i.e. 25% of initiation and over
40% of engagement

Overall initiation and engagement rates of
29.6% and 30.1%. Patients who were
female, not married, younger, and had
their SUDs identified in a SUD or
psychiatric specialty settings had higher
rates. Engagement rates higher when
treatment initiation was in outpatient
settings.

Results

No

No

No

No

No

No

No

Specific to OUD?

VHA = Veterans Health Administration; AOD = Alcohol or other drug; SMI = serious mental illness; RCT = randomized controlled trial; TAU = Treatment as usual; AOR = Adjusted odds ratio; Federally
Qualified Health Center; EHR = Electronic Health Records.

HEDIS
Initiation and
Engagement

HEDIS
Initiation and
Engagement

Harris & Bowe,
2008

Harris, Bowe,
Finney, &
Humphreys, 2009

Measure

Article

Author Manuscript

Studies investigating predictors of measure completion.

Author Manuscript
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Author Manuscript

Author Manuscript

Measure

HEDIS engagement

HEDIS engagement

Garnick, Lee,
O’Brien, et al.,
2012

Acevedo,
Garnick, Ritter,
Lundgren, &
Horgan, 2016
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Dunigan,
Acevedo,
Campbell, et
al., 2014

HEDIS Engagement

HEDIS engagement

Garnick,
Horgan,
Acevedo, et al.,
2014

Employment

HEDIS initiation and
engagement

Garnick,
Horgan, Lee, et
al., 2007

Criminal justice

HEDIS engagement

HEDIS initiation and
engagement

Harris,
Humphreys,
Bowe, Tiet, &
Finney, 2008

Harris,
Humphreys, &
Finney, 2007

Clinical outcomes and substance use

Article

Public sector
outpatient
treatment in
Washington state

Public sector
AOD treatment
centers in 4 states

Oklahoma,
publicly funded
outpatient
treatment

AOD outpatient
treatment
facilities in
Massachusetts

Outpatient
multisite pilot
study across 12
states;
adolescents

VHA

VHA, 110 SUD
treatment
programs across
73 facilities

Setting

Administrative,
employment, and
criminal justice data
including self-report

Administrative linked
with criminal justice
data

Administrative data,
client self-report

Administrative data

Secondary data, 28
outpatient clinics

Administrative and
survey data

Self-administered ASI

Data source

N = 7570
patients

Employment outcomes

Criminal justice outcomes

Detoxification admissions

N = 11,591
patients

N = 106,662
patients

Substance use outcomes

N = 1491
patients

Criminal justice outcomes

ASI composite drug, alcohol,
and legal scores at patient
level

N = 2789
patients

N = 5328
clients

ASI composite drug and
alcohol scores at the facility
level approximately 7 months
after patient intake

N = 5723
patients

Sample size

Primary outcome

Author Manuscript

Outcomes among patients satisfying quality measures.

For clients with prior criminal
justice involvement, engagement
was associated with both greater
employment (44.7% vs. 38.8%. p

Those who engaged had
significantly lower risk of any
arrest in all four states studied
(HR range 0.73–0.83)

Engagement, but not initiation,
was associated with lower risk
(HR: 0.73 95% CI 0.62, 0.87) of
subsequent arrest and
incarceration

Engaged patients had lower
detoxification admission in year
following index outpatient visit
(HR = 0.87, p < .01) among
clients in AOD treatment

Adolescents who engaged
reported had lower risk of
substance use (AOR 0.60 95% CI
0.41, 0.87), alcohol use (AOR
0.63 95% CI 0.45, 0.87), heavy
alcohol use (AOR 0.53 95% CI
0.33, 0.86), or marijuana use
(AOR 0.64 95% CI 0.45, 0.93)

Patients who engaged had
statistically significant but
clinically modest gains in all
scores, with greater effects for
alcohol and legal outcomes for
patients seen in outpatient
settings

Patients receiving care at
facilities with higher rates of
Initiation has modestly greater
improvements in ASI drug (but
not alcohol) composite scores
when adjusting for facility casemix characteristics

Results

No

No

N

No

No

No

No

Specific to OUD?

Author Manuscript

Table 4
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Author Manuscript
VHA

VHA,
retrospective
cohort study

VHA, inpatient
and outpatient

Cohort study of
VHA patients
with co-occurring
disorders (COD)

Administrative data and
phone survey

Administrative data

Administrative data

Administrative data

Self-reported perceived
improvement on the ECHO

12 and 24 month mortality
among patients with OUD

N = 31,016
patients

N = 2074
patients

12 and 24 month mortality

12 and 24 month mortality

Primary outcome

N = 339,966
patients

N = 144,045
patients

Sample size

Engagement, but not Initiation,
was associated with perceived
improvement (Coeff 0.25, p = .
006)

MAT continuity was not
associated with decreased
mortality however not being
prescribed opioids or
benzodiazepines, receipt of any
psychosocial treatment, and
quarterly physician visits were
significantly associated with
lower mortality at both 12 and 24
months

AOR of 12-month mortality with
initiation = 0.86, p = .001 and
engagement = 0.65, p < .001; and
24-month mortality with
initiation = 0.88, p = .005 and
engagement = 0.78, p < .001

Initiation associated with 15%
decrease and engagement
associated with 31% decrease in
12-month mortality. Increasing
numbers of visits associated with
further reductions in mortality.

< .01) and higher wages
($12,537 vs. $11,338) in the year
following treatment

Results

No

Yes

No

No

Specific to OUD?

VHA = Veterans Health Administration; ASI = Addiction Severity Index; AOD = Alcohol or other drug; TAU = Treatment as usual; AOR = Adjusted odds ratio; CI = Confidence interval; ECHO =
Experience of Care and Health Outcomes; HEDIS=Healthcare Effectiveness Data Information Set.

Hepner,
Paddock,
Watkins, et al.,
2017

HEDIS initiation and
engagement

MAT continuity (3
months)

Watkins,
Paddock,
Hudson, et al.,
2017

Patient satisfaction

HEDIS initiation and
engagement

HEDIS initiation and
engagement

Paddock,
Hepner,
Hudson, et al.,
2017

Watkins,
Paddock,
Hudson, et al.,
2016

Mortality

Data source

Author Manuscript
Setting

Author Manuscript

Measure

Author Manuscript

Article
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